Point72 Asia Singapore Pte. Ltd. Buys Shares of 2,004 Guardant Health, Inc. (NASDAQ:GH)

Point72 Asia Singapore Pte. Ltd. purchased a new position in shares of Guardant Health, Inc. (NASDAQ:GH) in the 4th quarter, according to the company in its most recent filing with the SEC. The fund purchased 2,004 shares of the company’s stock, valued at approximately $61,000.

Other institutional investors and hedge funds have also modified their holdings of the company. Guyasuta Investment Advisors Inc. bought a new position in Guardant Health during the fourth quarter worth about $206,000. Entropy Technologies LP bought a new stake in shares of Guardant Health in the 4th quarter valued at about $377,000. Stifel Financial Corp raised its position in shares of Guardant Health by 25.1% in the 4th quarter. Stifel Financial Corp now owns 49,927 shares of the company’s stock valued at $1,525,000 after acquiring an additional 10,006 shares during the period. Raymond James Financial Inc. bought a new position in Guardant Health during the 4th quarter worth approximately $2,211,000. Finally, Swiss National Bank grew its holdings in Guardant Health by 1.0% during the fourth quarter. Swiss National Bank now owns 241,900 shares of the company’s stock valued at $7,390,000 after purchasing an additional 2,500 shares during the period. 92.60% of the stock is owned by institutional investors.

Guardant Health Stock Up 0.5%

NASDAQ GH opened at $40.67 on Monday. Guardant Health, Inc. has a 12-month low of $20.14 and a 12-month high of $52.92. The firm’s 50 day moving average is $43.81 and its 200-day moving average is $39.76. The company has a market capitalization of $5.04 billion, a PE ratio of -11.42 and a beta of 1.49.

Guardant Health (NASDAQ:GH) last issued its quarterly earnings results on Wednesday, April 30th. The company reported ($0.49) EPS for the quarter, topping the consensus estimate of ($0.57) by $0.08. Guardant Health had a negative net margin of 59.05% and a negative return on equity of 19,157.20%. The firm had revenue of $203.47 million for the quarter, compared to analysts’ expectations of $189.91 million. During the same period in the previous year, the firm posted ($0.46) EPS. The company’s revenue for the quarter was up 20.8% on a year-over-year basis. As a group, sell-side analysts expect that Guardant Health, Inc. will post -2.9 EPS for the current year.

Analyst Upgrades and Downgrades

GH has been the subject of several recent analyst reports. Mizuho started coverage on shares of Guardant Health in a research note on Thursday, April 10th. They issued an “outperform” rating and a $55.00 target price for the company. UBS Group upped their price objective on shares of Guardant Health from $65.00 to $70.00 and gave the company a “buy” rating in a research report on Thursday, May 1st. The Goldman Sachs Group raised their price objective on Guardant Health from $49.00 to $56.00 and gave the stock a “buy” rating in a research note on Friday, February 21st. Canaccord Genuity Group boosted their target price on Guardant Health from $60.00 to $65.00 and gave the company a “buy” rating in a research note on Thursday, May 1st. Finally, Stifel Nicolaus increased their price target on Guardant Health from $53.00 to $60.00 and gave the stock a “buy” rating in a report on Thursday, May 1st. Twenty-one investment analysts have rated the stock with a buy rating and one has given a strong buy rating to the company. According to data from MarketBeat, Guardant Health currently has an average rating of “Buy” and an average price target of $52.32.

Insider Buying and Selling

In other Guardant Health news, CEO Amirali Talasaz sold 106,784 shares of the stock in a transaction on Thursday, May 1st. The shares were sold at an average price of $49.01, for a total value of $5,233,483.84. Following the completion of the sale, the chief executive officer now owns 2,202,672 shares in the company, valued at $107,952,954.72. This trade represents a 4.62% decrease in their ownership of the stock. The sale was disclosed in a legal filing with the SEC, which is available through this link. Over the last quarter, insiders have sold 107,132 shares of company stock worth $5,249,355. Corporate insiders own 6.10% of the company’s stock.

About Guardant Health

Guardant Health, Inc, a precision oncology company, provides blood and tissue tests, data sets, and analytics in the United States and internationally. The company provides Guardant360; Guardant360 LDT; Guardant360 CDx Test; Guardant360 Response Test; Guardant360 TissueNext Test; GuardantINFINITY Test; GuardantConnect, an integrated software-based solution designed for clinical and biopharmaceutical customers to connect patients tested with assays with actionable alterations with potentially relevant clinical studies; GuardantOMNI Test for advanced stage cancer; and GuardantINFORM, an in-silico research platform for tumor evolution and treatment resistance across various biomarker-driven cancers.